Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAK…
Industry Peers
Biotechnology| Headline | Source | Time |
|---|---|---|
Yesterday | ||
Harmony Biosciences Announces Preliminary Q2 Revenue, CFO Transition — Says Executive’s Departure Not Due To Any Disagreement Harmony Biosciences announced the appointment of Stephen Mollichella, SVP and Controller, as Interim Principal Financial Officer to ensure continuity in financial leadership while it searches for a permanent CFO. | ||
This week | ||
Wall Street Analysts See a 27.35% Upside in Harmony Biosciences (HRMY): Can the Stock Really Move This High? The mean of analysts' price targets for Harmony Biosciences (HRMY) points to a 27.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock. | ||
Zacks.com featured highlights Harmony, StoneCo, General Motors, Hewlett and Nexa Harmony, StoneCo, General Motors, Hewlett and Nexa have been highlighted in this Screen of The Week article. | ||
HRMY vs. AMGN: Which Stock Is the Better Value Option? HRMY vs. AMGN: Which Stock Is the Better Value Option? | ||
5 Low Price-to-Book Value Stocks to Buy in July for Solid Returns Five low price-to-book stocks pass our value screens with low P/B, P/S and PEG metrics, highlighting their earnings growth potential. | ||
Are Investors Undervaluing Harmony Biosciences (HRMY) Right Now? Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks. | ||
Older | ||